Cannabis Dosing for ADHD UK: Focus & Attention

Cannabis Dosing for ADHD in the UK: A Practical Guide

Medical Disclaimer: This guide is for educational purposes only and does not constitute medical advice. Cannabis-based products for medicinal use (CBPMs) should only be used under the supervision of a specialist physician licensed to prescribe in the UK. Always consult your healthcare provider before starting, adjusting, or discontinuing any treatment. Individual responses to cannabis vary significantly and dosing must be personalised to your circumstances.

Understanding ADHD and Cannabis
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterised by persistent difficulties with attention, impulse control, and executive function. In the UK, ADHD affects approximately 2-5% of adults and 3-5% of children, though many cases remain undiagnosed. The condition involves dysregulation of dopamine and noradrenaline in the prefrontal cortex and striatum, which impairs focus, working memory, and emotional regulation.

Traditional ADHD management relies on stimulant medications (methylphenidate, amphetamines) and non-stimulant alternatives (atomoxetine, guanfacine). However, an emerging interest in cannabis-based treatments has prompted clinical exploration, particularly for patients who experience inadequate response or intolerable side effects from conventional medications. For more context on accessing specialist care, see our guide on medical cannabis UK.

Evidence Base and Current Controversies

The evidence supporting cannabis for ADHD remains limited and mixed. Some small studies and case reports suggest that cannabidiol (CBD) may help reduce anxiety, improve sleep, and enhance emotional regulation—factors that often co-occur with ADHD. Low-dose tetrahydrocannabinol (THC) has been proposed to enhance dopaminergic signalling, potentially improving attention in some individuals.

However, large-scale randomised controlled trials specifically examining cannabis efficacy for ADHD are scarce. High-dose THC has been associated with cognitive impairment, anxiety, and psychosis risk, particularly in vulnerable populations. Many specialists remain cautious about THC-containing products for ADHD treatment. The UK regulatory position reflects this caution: cannabis-based products are scheduled as controlled medicines, and prescribing is limited to specialist settings where conventional treatments have failed or are unsuitable.

Key controversies include the optimal CBD-to-THC ratio, whether THC is necessary at all, and whether cannabis offers sustained symptom relief or merely temporary management. Research is ongoing, and individual prescribing decisions should be based on shared decision-making with your specialist.

UK Prescribing Approach: Start Low, Go Slow

UK specialists follow a conservative, individualised approach to cannabis dosing, particularly for ADHD. The principle of “start low, go slow” is fundamental. This approach recognises that cannabis dosing is highly person-dependent, influenced by genetics, tolerance, concurrent medications, and underlying health conditions.

The prescribing pathway begins with a thorough assessment by a specialist (usually a psychiatrist or pain consultant with cannabis prescribing accreditation). Only after conventional treatments have been exhausted, or deemed unsuitable, will cannabis be considered. For guidance on obtaining a prescription, consult how to get a medical cannabis prescription.

Typical Dose Ranges

CBD (Cannabidiol)

CBD is non-intoxicating and generally well-tolerated. For ADHD-related symptoms such as anxiety and sleep disturbance, typical starting doses range from 75–150 mg daily, divided into two doses (morning and evening). Doses are gradually increased by 50–100 mg increments every 1–2 weeks, depending on response and tolerability. Therapeutic doses typically plateau between 200–600 mg daily, though some patients benefit from higher amounts (up to 1000 mg daily). Higher doses may cause drowsiness or gastrointestinal effects in some individuals.

Low-Dose THC

If THC is included in a formulation, UK specialists typically recommend starting at 1–2.5 mg daily, taken in the evening to minimise intoxication and cognitive impact during daytime hours. Increments are made cautiously, usually by 1–2 mg weekly, with most therapeutic doses remaining below 10 mg daily for ADHD. This contrasts sharply with pain management, where doses may be considerably higher. THC dosing is particularly individualised; some patients experience benefit at sub-5 mg doses, whilst others find no additional benefit.

Routes of Administration

Oil Drops (Oral Tinctures)

Cannabis oils are the most commonly prescribed format in the UK. They offer precise dosing via dropper, allowing fine-tuned titration. Oils can be taken sublingually (under the tongue) for faster absorption or swallowed with food. Sublingual administration typically produces effects within 15–30 minutes, whilst oral ingestion takes 1–2 hours but provides longer, more stable effects. Oils are ideal for ADHD patients requiring consistent daily dosing.

Capsules

Standardised capsules provide convenience and consistent dosing. However, they offer less flexibility for titration compared to oils. Some capsule formulations combine CBD and THC in fixed ratios. Absorption via capsules follows the same oral kinetics as oils mixed with food, typically 1–2 hours to peak effect.

Whole-Plant Dried Flowers

Though less commonly prescribed for ADHD specifically in the UK, some patients inhale via vaporisation (not smoking, which damages lung tissue). Inhalation offers rapid onset (within minutes) but is less suitable for precise ADHD dosing due to wider inter-dose variability. Most UK ADHD prescriptions favour oils or capsules.

Titration Strategy

A typical ADHD titration protocol might look like this:

Weeks 1–2: Start with 100 mg CBD daily (50 mg morning, 50 mg evening) with no THC.

Weeks 3–4: If well-tolerated and minimal symptom change, increase to 150 mg CBD daily.

Weeks 5–6: If further benefit is needed, increase to 200 mg CBD daily. Introduce low-dose THC (1–2 mg evening) if approved by your best UK cannabis clinics.

Weeks 7–12: Continue slow increments of both CBD and THC, monitoring effects on focus, sleep, mood, and any adverse effects. Aim for a stable dose by week 8–12.

The entire titration period may take 8–16 weeks. Patience is essential; rushing titration increases the risk of side effects and false treatment conclusions.

Focus and Sleep Considerations

CBD generally promotes calm alertness without sedation at lower doses, making it suitable for daytime use. However, some patients experience drowsiness, particularly at doses above 300 mg daily. If this occurs, shift the higher dose to evening.

Low-dose THC in the evening may improve sleep quality, which is crucial for ADHD management—poor sleep exacerbates ADHD symptoms. However, THC can impair next-day alertness in some individuals; monitor this closely. If daytime THC is necessary (rare for ADHD), use microdoses (1–2 mg) taken with breakfast.

Avoid using THC-dominant products during work or study hours, as THC impairs attention and working memory at standard doses.

When to Contact Your UK best UK cannabis clinics or Psychiatrist

Seek immediate specialist advice if you experience: